Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc. (NASDAQ: ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced that management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026 at 1:00 p.m. GMT.
A live webcast of the presentation will be available in the Investors section of Electra’s website at ir.electra-therapeutics.com and a replay will be available following the event.
About Electra Therapeutics
Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function. The company’s lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory T-cell and natural-killer cell malignancies. ELA822, the company’s second clinical-stage product candidate, is a novel SIRPγ-specific antibody being developed for a broad range of chronic T cell-mediated immune and inflammatory diseases. For more information, please visit electra-therapeutics.com and follow us on LinkedIn.
Contacts:
Investor Contact:
Renee Leck, THRUST
Renee@thrustsc.com
Media Contact:
Sarah Sutton, THRUST
sarah@thrustsc.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
